Table 3. Factors predicting overall survival.
| Characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (yr) | 1.23 (0.91–1.67) | 0.162 | - | - | |
| CCI | 0.033 | 0.093 | |||
| >1 | Reference | Reference | |||
| <1 | 0.42 (0.25–0.94) | 0.56 (0.29–1.10) | |||
| ASA score | 0.73 (0.31–1.72) | 0.485 | - | - | |
| ECOG performance status | 0.78 (0.33–1.82) | 0.571 | - | - | |
| CA125 levels | 0.99 (0.98–1.01) | 0.881 | - | - | |
| Type of surgical approach | 0.014 | 0.027 | |||
| Primary cytoreductive surgery | Reference | Reference | |||
| IDS | 3.00 (1.25–7.20) | 2.95 (1.12–7.74) | |||
| RD | 0.064 | 0.296 | |||
| No | Reference | Reference | |||
| Yes | 2.25 (0.95–5.30) | 1.78 (0.60–5.26) | |||
| Optimal cytoreduction | 0.130 | - | |||
| RD <1 cm | Reference | - | |||
| RD >1 cm | 1.97 (0.81–4.75) | - | |||
| FIGO stage of disease | 0.018 | 0.172 | |||
| Stage III | Reference | Reference | |||
| Stage IV | 3.46 (1.23–9.70) | 2.24 (0.70–7.13) | |||
| Lymph node status | 0.226 | - | |||
| Negative | Reference | - | |||
| Positive | 0.28 (0.03–2.15) | - | |||
ASA, American Society of Anesthesiologists; CA125, cancer antigen 125; CI, confidence interval; CCI, Charlson comorbidity index; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; IDS, interval debulking surgery; RD, residual disease.